Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + fluorouracil + vinorelbine
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A chemotherapy combination regimen consisting of cyclophosphamide, 5-fluorouracil, and vinorelbine used primarily for the treatment of locally advanced or metastatic breast cancer. This combination has shown efficacy comparable to anthracycline-containing regimens while maintaining a manageable toxicity profile, making it suitable for patients who have been extensively exposed to anthracyclines during adjuvant therapy or who have contraindications to their use.
02
Targets
MicrotubuleDNATS (Thymidylate synthase)
Beyond the preview
Go deeper on cyclophosphamide + fluorouracil + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + fluorouracil + vinorelbine.